BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 34505396)

  • 21. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
    O'Cearbhaill R; Zhou Q; Iasonos A; Hensley ML; Tew WP; Aghajanian C; Spriggs DR; Lichtman SM; Sabbatini PJ
    Gynecol Oncol; 2010 Mar; 116(3):326-31. PubMed ID: 19944454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions.
    Broome CB; Schiff RI; Friedman HS
    Med Pediatr Oncol; 1996 Feb; 26(2):105-10. PubMed ID: 8531847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database.
    Leone R; Conforti A; Venegoni M; Motola D; Moretti U; Meneghelli I; Cocci A; Sangiorgi Cellini G; Scotto S; Montanaro N; Velo G
    Drug Saf; 2005; 28(6):547-56. PubMed ID: 15924506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different clinical features of anaphylaxis according to cause and risk factors for severe reactions.
    Kim SY; Kim MH; Cho YJ
    Allergol Int; 2018 Jan; 67(1):96-102. PubMed ID: 28602247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.
    Li Q; Cohn D; Waller A; Backes F; Copeland L; Fowler J; Salani R; O'Malley D
    Gynecol Oncol; 2014 Oct; 135(1):90-4. PubMed ID: 25110329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin.].
    Wang HB; Shen K; Yang JX; Huang HF; Li Y; Wu M; Pan LY
    Zhonghua Fu Chan Ke Za Zhi; 2009 Nov; 44(11):837-40. PubMed ID: 20079036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
    Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
    Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are antineoplastic drug acute hypersensitive reactions a submerged or an emergent problem? Experience of the Medical Day Hospital of the Fondazione IRCCS Istituto Nazionale Tumori.
    Ferrari LA; Fanetti G; Rossi FG; Brambilla MC; Re B; Buzzoni R
    Tumori; 2014; 100(1):9-14. PubMed ID: 24675484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.
    Rosell R; Gatzemeier U; Betticher DC; Keppler U; Macha HN; Pirker R; Berthet P; Breau JL; Lianes P; Nicholson M; Ardizzoni A; Chemaissani A; Bogaerts J; Gallant G
    Ann Oncol; 2002 Oct; 13(10):1539-49. PubMed ID: 12377641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital.
    Keating K; Walko C; Stephenson B; O'Neil BH; Weiss J
    J Oncol Pharm Pract; 2014 Dec; 20(6):409-16. PubMed ID: 24243920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010.
    Renaudin JM; Beaudouin E; Ponvert C; Demoly P; Moneret-Vautrin DA
    Allergy; 2013 Jul; 68(7):929-37. PubMed ID: 23741979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.
    Brooks GA; Austin AM; Uno H; Dragnev KH; Tosteson ANA; Schrag D
    JAMA Netw Open; 2018 Oct; 1(6):e183023. PubMed ID: 30646220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of Omalizumab in Rapid Drug Desensitization in Patients With Severe Anaphylaxis Induced by Carboplatin: Open Questions.
    Sánchez-Morillas L; Casado Herráez A; Rubio-Perez M; Robledo Echarren T; González Gutiérrez ML; Cimarra M; Vázquez Cortés S; Cerecedo I; Fernández-Rivas M
    J Investig Allergol Clin Immunol; 2020; 30(4):298-300. PubMed ID: 32101175
    [No Abstract]   [Full Text] [Related]  

  • 39. Anaphylaxis caused by intravenous fluorescein: clinical characteristics and review of literature.
    Ha SO; Kim DY; Sohn CH; Lim KS
    Intern Emerg Med; 2014 Apr; 9(3):325-30. PubMed ID: 24293212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas.
    Pasternak AL; Link NA; Richardson CM; Rose PG
    Pharmacotherapy; 2016 Jul; 36(7):723-30. PubMed ID: 27196693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.